Table 2 Summary of findings for mortality outcomes [35]
Burden of disease measure | Type of antimicrobial resistance | Number of participants (studiesa) | Relative effect sOR (95% CI) | Absolute effect Risk difference (95% CI) | Certainty of the evidence (GRADE)b | Commentc |
|---|---|---|---|---|---|---|
30-day mortality | Third-generation cephalosporin | 31,934 (23 studies) | 2.02 (1.66–2.46) | 112 more deaths per 1000 (from 76 to 151 more) |
| Evidence to support upgrading due to strong association and no evidence to support downgrading |
Quinolone | 27,703 (8 studies) | 1.49 (1.23–1.82) | 58 more deaths per 1000 (from 28 to 93 more) |
| No evidence to support downgrading or upgrading | |
MDR | 6506 (4 studies) | 1.63 (1.54–1.71) | 96 more deaths per 1000 (from 83 to 106 more) |
| No evidence to support downgrading or upgrading | |
All-cause mortality | Third-generation cephalosporin | 40,623 (51 studies) | 2.27 (1.92–2.70) | 130 more deaths per 1000 (from 98 to 166 more) |
| Evidence to support upgrading due to strong association and no evidence to support downgrading |
Quinolone | 31,324 (16 studies) | 1.72 (1.40–2.12) | 82 more deaths per 1000 (from 48 to 121 more)d |
| No evidence to support downgrading or upgrading | |
MDR | 6814 (5 studies) | 1.63 (1.55–1.70) | 92 more deaths per 1000 (from 81 to 100 more) |
| No evidence to support downgrading or upgrading | |
Bacterium-attributable mortality | Third-generation cephalosporin | 327 (3 studies) | 1.76 (0.84–3.70) | 78 more deaths per 1000 (from 18 fewer to 225 more) |
| Downgraded due to serious inconsistency and imprecision. No evidence to support upgrading. |
Quinolone | – | – | – | – | Not reported | |
MDR | – | – | – | – | Not reported |
